Development of Chronic Myeloid Leukaemia in Patients Treated with Anti-VEGF Therapies for Clear Cell Renal Cell Cancer

References

• Di Lorenzo G , PortaC, BellmuntJet al. Toxicities of targeted therapy and their management in kidney cancer. Eur. Urol.59(4), 526–540 (2011).
   PubMed Web of Science ®Google Scholar
• Guevremont C , AlaskerA, KarakiewiczPI. Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma. Curr. Opin. Support. Palliat. Care3(3), 170–179 (2009).
   PubMedGoogle Scholar
• Hutson TE , FiglinRA, KuhnJG, MotzerRJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. The Oncologist13(10), 1084–1096 (2008).
   PubMed Web of Science ®Google Scholar
• Schmidinger M , BellmuntJ. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat. Rev.36(5), 416–424 (2010).
   PubMed Web of Science ®Google Scholar
• Aparicio-Gallego G , BlancoM, FigueroaAet al. New insights into molecular mechanisms of sunitinib-associated side effects. Mol. Cancer Ther.10(12), 2215–2223 (2011).
   PubMed Web of Science ®Google Scholar
• Fabian MA , BiggsWH3rd, TreiberDKet al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol.23(3), 329–336 (2005).
   PubMed Web of Science ®Google Scholar
• Stein MN , FlahertyKT. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma. Clin. Cancer Res.13(13), 3765–3770 (2007).
   PubMed Web of Science ®Google Scholar
• Cohen RB , OudardS. Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities. Invest. New Drugs.30(5), 2066–2079 (2012).
   PubMed Web of Science ®Google Scholar
• Oh WK , McdermottD, PortaCet al. Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review. Int. J. Oncol.44(1), 5–16 (2014).
   PubMed Web of Science ®Google Scholar
• Michel MS , VervenneW, De SantisMet al. SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). J. Clin. Oncol.32(Suppl.4), 393 abstr. (2014).
   Web of Science ®Google Scholar
• Gore ME , SzczylikC, PortaCet al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol.10(8), 757–763 (2009).
   PubMed Web of Science ®Google Scholar
• Giehl M , LeitnerA, HaferlachCet al. Detection of centrosome aberrations in disease-unrelated cells from patients with tumor treated with tyrosine kinase inhibitors. Eur. J. Haematol.85(2), 139–148 (2010).
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C , BjarnasonG, BurnettPet al. Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. Oncologist16(5), 543–553 (2011).
   PubMed Web of Science ®Google Scholar
• Specchia G , BuquicchioC, AlbanoFet al. Non-treatment-related chronic myeloid leukemia as a second malignancy. Leuk. Res.28(2), 115–119 (2004).
   PubMed Web of Science ®Google Scholar
• Nishikubo CY , KunkelLA, FiglinRet al. An association between renal cell carcinoma and lymphoid malignancies. A case series of eight patients. Cancer78(11), 2421–2426 (1996).
   PubMed Web of Science ®Google Scholar
• Al-Najjar F , JarkowskiA3rd. Treatment of concurrent metastatic renal cell carcinoma and chronic myelogenous leukemia--easier said than done? A case report. J. Oncol. Pharm. Pract.17(4), 436–439 (2011).
   PubMedGoogle Scholar
• Pal SK , GuptaRK, DosikG, FiglinRA. Concomitant renal cell carcinoma and chronic myelogenous leukemia: use of a targeted approach. Curr. Oncol.16(2), 44–47 (2009).
   PubMed Web of Science ®Google Scholar
• Escudier B , EisenT, StadlerWMet al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med.356(2), 125–134 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , HutsonTE, TomczakPet al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med.356(2), 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Czarnecka A , SobczukP, BoguszK, SpychalskaM, SzczylikC. Survival, safety and treatment response duration in “real world” patients with metastatic clear cell renal cancer – an update from clinical practice. BJU Int.112(s3), 1–17 (2013).
   Google Scholar
• Szmit S , ZaborowskaM, Wasko-GrabowskaAet al. Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib. Kidney Blood Press Res.35(6), 468–476 (2012).
   PubMed Web of Science ®Google Scholar
• Czarnecka AM , OborskaS, RzepeckiP, SzczylikC. Development of CML in the course of ccRCC treatment with tyrosine kinase inhibitors – clinical report with molecular model. BJU Int.112(s3), 1–17 (2013).
   Google Scholar
• Szmit S , LangiewiczP, ZlnierekJet al. Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines. Kidney Blood Press Res.35(1), 18–25 (2012).
   PubMed Web of Science ®Google Scholar
• Jimenez VH . Coexistence between renal cell cancer and Hodgkin’s lymphoma: a rare coincidence. BMC urology6(10), (2006).
   PubMedGoogle Scholar
• Sternberg CN , HawkinsRE, WagstaffJet al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur. J. Cancer.49(6), 1287–1296 (2013).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , EscudierB, OudardSet al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer116(18), 4256–4265 (2010).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , HutsonTE, TomczakPet al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol.27(22), 3584–3590 (2009).
   PubMed Web of Science ®Google Scholar
• Molina AM , JiaX, FeldmanDRet al. Long-term response to sunitinib therapy for metastatic renal cell carcinoma. Clin. Genitourin. Cancer11(3), 297–302 (2013).
   PubMed Web of Science ®Google Scholar
• Molina AM , LinX, KorytowskyBet al. Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials. Eur. J. Cancer50(2), 351–358 (2014).
   PubMed Web of Science ®Google Scholar
• Verma D , KantarjianH, StromSSet al. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood118(16), 4353–4358 (2011).
   PubMed Web of Science ®Google Scholar
• Roy L , GuilhotJ, MartineauG, LarcheeR, GuilhotF. Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia. Leukemia19(9), 1689–1692 (2005).
   PubMed Web of Science ®Google Scholar
• Ohishi K , KatayamaN, ItohRet al. Accelerated cell-cycling of hematopoietic progenitors by the flt3 ligand that is modulated by transforming growth factor-beta. Blood87(5), 1718–1727 (1996).
   PubMed Web of Science ®Google Scholar
• Sonoda E , HocheggerH, SaberiA, TaniguchiY, TakedaS. Differential usage of non-homologous end-joining and homologous recombination in double strand break repair. DNA repair5(9–10), 1021–1029 (2006).
   PubMed Web of Science ®Google Scholar
• Pasternak G , HochhausA, SchultheisB, HehlmannR. Chronic myelogenous leukemia: molecular and cellular aspects. J. Cancer Res. Clin. Oncol.124(12), 643–660 (1998).
   PubMed Web of Science ®Google Scholar
• Gollin SM . Mechanisms leading to nonrandom, nonhomologous chromosomal translocations in leukemia. Semin. Cancer Biol.17(1), 74–79 (2007).
   PubMed Web of Science ®Google Scholar
• Salles D , MencalhaAL, IrenoIC, WiesmullerL, AbdelhayE. BCR-ABL stimulates mutagenic homologous DNA double-strand break repair via the DNA-end-processing factor CtIP. Carcinogenesis32(1), 27–34 (2011).
   PubMed Web of Science ®Google Scholar
• Jamieson CH . Chronic myeloid leukemia stem cells. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Prog.436–442 (2008).
   Google Scholar
• Chakraborty S , StarkJM, SunCLet al. Chronic myelogenous leukemia stem and progenitor cells demonstrate chromosomal instability related to repeated breakage-fusion-bridge cycles mediated by increased nonhomologous end joining. Blood119(26), 6187–6197 (2012).
   PubMed Web of Science ®Google Scholar
• Skorski T , SzczylikC, MalaguarneraL, CalabrettaB. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides. Folia Histochem. Cytobiol.29(3), 85–89 (1991).
   PubMed Web of Science ®Google Scholar
• Szczylik C , SkorskiT, NicolaidesNCet al. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science253(5019), 562–565 (1991).
   PubMed Web of Science ®Google Scholar
• Era T , WitteON. Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate. Proc. Natl Acad. Sci. USA97(4), 1737–1742 (2000).
   PubMed Web of Science ®Google Scholar
• Carroll M . BCR/ABL and chromosomal instability: debate resolved. Blood119(26), 6180–6181 (2012).
   PubMed Web of Science ®Google Scholar
• Slupianek A , PoplawskiT, JozwiakowskiSKet al. BCR/ABL stimulates WRN to promote survival and genomic instability. Cancer Res.71(3), 842–851 (2011).
   PubMed Web of Science ®Google Scholar
• Era T . Bcr-Abl is a “molecular switch” for the decision for growth and differentiation in hematopoietic stem cells. Int. J. Hematol.76(1), 35–43 (2002).
   PubMed Web of Science ®Google Scholar
• Yadav A , KumarB, TeknosTN, KumarP. Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins. Mol. Cancer Ther.10(7), 1241–1251 (2011).
   PubMed Web of Science ®Google Scholar
• Yang J , IkezoeT, NishiokaCet al. Long-term exposure of gastrointestinal stromal tumor cells to sunitinib induces epigenetic silencing of the PTEN gene. Int. J. Cancer.130(4), 959–966 (2012).
   PubMed Web of Science ®Google Scholar
• Peng C , ChenY, YangZet al. PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice. Blood115(3), 626–635 (2010).
   PubMed Web of Science ®Google Scholar
• Holland AJ , FachinettiD, Da CruzSet al. Polo-like kinase 4 controls centriole duplication but does not directly regulate cytokinesis. Mol. Biol. Cell.23(10), 1838–1845 (2012).
   PubMed Web of Science ®Google Scholar
• Giehl M , FabariusA, FrankOet al. Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability. Leukemia19(7), 1192–1197 (2005).
   PubMed Web of Science ®Google Scholar
• Dolence JJ , GwinK, FrankE, MedinaKL. Threshold levels of Flt3-ligand are required for the generation and survival of lymphoid progenitors and B-cell precursors. Eur. J. Immunol.41(2), 324–334 (2011).
   PubMed Web of Science ®Google Scholar
• Lyman SD , JacobsenSE. c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood91(4), 1101–1134 (1998).
   PubMed Web of Science ®Google Scholar
• Kitagawa D , GoudaM, KiriiYet al. Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase. J. Biochem.151(1), 47–55 (2012).
   PubMed Web of Science ®Google Scholar
• Hume DA , MacdonaldKP. Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood119(8), 1810–1820 (2012).
   PubMed Web of Science ®Google Scholar
• Jiang X , ForrestD, NicoliniFet al. Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate. Blood116(12), 2112–2121 (2010).
   PubMed Web of Science ®Google Scholar
• Liang J , WuYL, ChenBJ, ZhangW, TanakaY, SugiyamaH. The C-kit receptor-mediated signal transduction and tumor-related diseases. Int. J. Biol. Sci.9(5), 435–443 (2013).
   PubMed Web of Science ®Google Scholar
• Ward AC , TouwI, YoshimuraA. The Jak–Stat pathway in normal and perturbed hematopoiesis. Blood95(1), 19–29 (2000).
   PubMed Web of Science ®Google Scholar
• Miranda MB , JohnsonDE. Signal transduction pathways that contribute to myeloid differentiation. Leukemia21(7), 1363–1377 (2007).
   PubMed Web of Science ®Google Scholar
• Schallier D , TrullemansF, FontaineC, DecosterL, De GreveJ. Tyrosine kinase inhibitor-induced macrocytosis. Anticancer Res.29(12), 5225–5228 (2009).
   PubMed Web of Science ®Google Scholar
• Rini BI , ChoueiriTK, ElsonPet al. Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer113(6), 1309–1314 (2008).
   PubMed Web of Science ®Google Scholar